

Annual Report
2002

New Jersey
Commission
on Cancer
Research

Dedicated to
Conquering Cancer
Through Scientific Research



James E. McGreevey
Governor

NEW JERSEY COMMISSION ON CANCER RESEARCH

2002 Annual Report

TABLE OF CONTENTS

Message from the Chairman / iii

Executive Summary / 1

See What Others Are Saying About Us! / 2

Status of Cancer in New Jersey / 3

Research Highlights / 5

2002: A Year in Review / 11

Revenue Summary / 22

NJCCR Members and Staff / 23

2002 Advisory Groups / 26



The Honorable James E. McGreevey Governor

Dear Governor McGreevey,

On behalf of my colleagues on the New Jersey State Commission on Cancer Research and the scores of Advisory Group volunteers who aid our efforts, it is my pleasure to present to you this report of the Commission's activities for 2002.



Since its creation by the Legislature in 1983 with passage of the Cancer Research Act (P.L. 83, Ch.6), the Commission has provided more than \$23 million dollars for cancer research in New Jersey. The Commission's mission and efforts to reduce cancer morbidity and mortality have helped build New Jersey's research infrastructure, served as a stimulus and incubator for additional funding sources, assisted in the creation of the Cancer Institute of New Jersey, and served as a model for similar programs around the country. Research grants awarded by the Commission have provided start-up funds for brilliant young investigators, aided more senior researchers to make changes in their areas of investigation, and introduced high school, college and graduate students to the potentials of research-oriented careers. Many of our grant winners have remained in New Jersey because of their awards. We have served as a catalyst for development of many organizational relationships for research and education, and by the development and implementation of research-related workshops, have stimulated innumerable collaborations.

The members of the Commission, its staff and Advisory Group members, and indeed, all citizens of New Jersey, are grateful for your enthusiastic support of our critically important efforts. We look forward to your continued commitment to the cause of cancer control.

With warmest personal regards,

**Paul E. Wallner, D.O., FACR
Chairman
NJCCR**

Executive Summary

Throughout its history, the New Jersey Commission on Cancer Research (NJCCR) has united with members of the cancer community so that we might work together to keep New Jersey on the cutting edge in the fight against cancer.

In 1983, the New Jersey Legislature, guided by advocates across the state, recognized the need to respond to the cancer epidemic. With the passage of the Cancer Research Act (PL.83, Ch.6), the tobacco tax was increased in New Jersey to create an ongoing source of funds to support the high human and economic costs of cancer. Each year, this tax provides new dollars that are devoted to research on the causes, prevention and treatment of cancer. Additional funds come from taxpayer donations on the state income tax return (Breast Cancer Research Fund), the Conquer Cancer License Plate and from private donations. The NJCCR administers these funds and supports research projects through a competitive process for scientists across the state at a variety of universities, research centers and other settings.

Early on in its development, the NJCCR recognized that the only sure strategy for success in its mission was to invest in the most talented people. With this in mind, the NJCCR has consistently supported talented young researchers seeking to break into the competitive world of cancer research, and senior investigators embarking on new research directions. A National Institutes of Health system of scientific peer-review is used in making its awards, which assures a rigorous and fair approach to all of its endeavors.

To date, the NJCCR has provided more than \$23 million dollars for over 500 research projects on cancer. This report presents the NJCCR's recent activities, goals, progress and plans for the challenges that lie ahead on the road to decreasing the human and economic burden of cancer for the people of New Jersey.

Mission Statement

To ensure that the citizens of New Jersey receive the fullest benefit of our nation's fight against cancer through the promotion and funding of research into the causes, prevention, and treatment of cancer.



"To date, the NJCCR has provided more than \$23 million dollars for over 500 research projects on cancer."

See What Others Are Saying About Us

***M**y heartfelt thanks to the NJCCR. This was really cutting edge research at a stage where the Federal agencies wouldn't touch it. Thanks to your support, it has reached "critical mass" where it has gained acceptance in the scientific community.*

Jonathan Dinman, Ph.D., Assistant Professor, Molecular Genetics and Microbiology, used his \$33,550 NJCCR grant to obtain \$1,513,591 in federal funding to study "Ribosomal Frameshifting as a Probe of 5S RRNA Function."

***S**o proud to be associated with you...so appreciative of the good you bring to New Jersey, and also the good that you allow others to bring. You have created such a special program.*

Mr. Keith DaCosta, Executive Vice President of 100 Black Men of New Jersey and Co-chair of the National Health and Wellness Committee of the 100 Black Men of America

***B**y enlisting the talents of highly qualified clinicians and basic scientists and the real life experiences of cancer survivors, the New Jersey Commission on Cancer Research Grant Program ensures that excellent science with potential for the greatest benefit to cancer patients is funded. In my opinion it is an outstanding state based research funding program, which should definitely be copied by other states.*

Robert P. Perry, Ph.D., a molecular biologist, holds the Fox Chase Cancer Center's Stanley P. Reimann Endowed Chair in Research and is the NJCCR's scientific review panel chair

***T**he South Jersey Breast Cancer Coalition is proud to support the New Jersey Commission on Cancer Research. The Resource Book for Cancer Patients is an invaluable tool for myself as well as other breast cancer survivors. This guide provides the answers to the tough questions and empowers the survivor's to cope with the strain that a cancer diagnosis can bring.*

Ms. Loretta Mikulski, Founder of the South Jersey Breast Cancer Coalition and survivor of breast cancer



Status of Cancer in New Jersey

In 2002 over 41,000 residents of New Jersey learned they had cancer and over 17,000 died of the disease. New Jersey also consistently ranks among the ten highest states for cancer incidence and mortality. The New Jersey State Cancer Registry estimates that there are currently over 350,000 of our relatives, friends, and neighbors living with a history of cancer, in the State. The economic costs of cancer are enormous. A recent analysis indicates that cancer-related costs to New Jersey are estimated at over \$5 billion per year. The burden from human suffering and sacrifice cannot be measured. It is for these reasons that the New Jersey Commission on Cancer Research (NJCCR) is dedicated to carrying out its mandate.

In the big picture, are we really making progress in cancer research?

The answer is a resounding “yes.” Thanks in large measure to the dedication and hard work of scientists across the nation, and especially in New Jersey, we are seeing real progress in the fight against cancer.

Just a few decades ago, cancer was a poorly understood disease that killed the great majority of those affected. In 1989, U.S. researchers won the Nobel Prize for discovering

how a normal cell can multiply out of control and become malignant because of defects in normal cellular genes. This profound insight and subsequent work of many others led researchers to a new era in cancer research.

In labs around the country, including New Jersey, scientists are using this new basic knowledge in their efforts to develop drugs that will specifically target altered genes or the protein products they specify. The hope is that these newer treatments will be more effective and less toxic than the treatments of today.

The bits and pieces of knowledge that have accumulated over the last three decades about genes and cells have begun to come together to present a more comprehensive picture. New technologies permit us to monitor the activities of 30,000 to 50,000 genes from a single cell and identify those that behave differently in the cancer cell.

This and other new molecular information promise to revolutionize cancer diagnosis, treatment and prevention. Diagnosis will improve because the molecular signature of the cancer cell will be detected earlier when many cancers can be cured by less invasive therapies. Treatment will be aided by new, highly effective therapeutics that are tailored to the particular molecular characteristics

of the cancer. Prevention will become possible because these specific interventions will have fewer side effects, permitting individuals at high risk to reduce those risks.

We are truly making progress, but for those who are touched by this disease, we are not making progress quickly enough. Furthermore, other recent negative trends threaten to overshadow our hard-won victories. The incidence of melanoma has been rising about 3% per year; adolescents are smoking and using tobacco products more and certain racial and ethnic and underserved groups continue to be disproportionately burdened by cancer.

How then can we continue to build on our recent accomplishments to make further much-

needed progress against cancer? Foremost, we must sustain the proven research programs that have enabled us to pursue a path of scientific excellence and discovery in cancer research even in difficult fiscal times. We must also ensure that the full promise of our research findings is realized by translating these discoveries rapidly from the laboratory into practical solutions that will benefit everyone.

Achieving these goals demand enormous investments in recruiting new scientists, acquiring new technologies and forging partnerships at all levels. The exciting possibility of making progress toward “eliminating cancer as a cause of human suffering and death” is making us impatient.

The NJCCR is committed to seeing that these advances improve life and hope for all cancer patients. Since 1983, the NJCCR has created an infrastructure that promotes discovery, works with some of the most innovative and productive scientists in the Nation and initiated ground-breaking programs such as the “Cancer & Aging: A Call to Action Conference” that have yielded critical knowledge, relevant to the quality of life for many cancer survivors.

To stay on this path, we need your support. As long as the army of dedicated researchers, patients, volunteers, donors, and doctors remain strong, a cure for cancer, once and for all, is at hand.



Research Highlights

In order to attain its goals, the NJCCR invests in the state's scientific infrastructure by supporting basic laboratory and preventive studies, as well as clinical protocols, and epidemiological and psychosocial research. The Commission's specialized advisory groups, along with the input from public advocates, assist the NJCCR in generating its research agenda.

The NJCCR applies its research dollars to the most promising areas many of which are not candidates for support by the larger funders. Projects are chosen based upon whether or not they can open promising new channels for investigation that national research funding systems can carry forward. For example, in 2002, the NJCCR offered a new type of Breast Cancer Research Award to encourage collaboration between nonaffiliated cancer research institutions. This type of research may not be well funded by other agencies, and it is our hope that bringing expertise from diverse laboratories into the fight against cancer will hold strong promise for breakthroughs.

The NJCCR uses a competitive peer-review process, similar to the methods used by the National Cancer Institute and the American Cancer Society, to ensure awards are based on the highest scientific merit. The majority of NJCCR seed grants have been

very successful in attracting national funds back to New Jersey for continued research. For every dollar the NJCCR has awarded, on average over \$4.65, has been returned to the state for continued research, strengthening the scientific infrastructure and New Jersey's economy. This is an outstanding return of more than **450%** on our State's investment.

As a result of its outstanding pioneering achievements, the NJCCR has gained national recognition by the National Cancer Advisory Board, and has been a model for other states.

Through its highly competitive grant program, four two year awards, three one year awards, four breast cancer research fund awards, and one award in response to our Breast Cancer Request for Application (RFA), were provided to investigators at non-profit research institutions throughout New Jersey in 2002.

"For every dollar the NJCCR has awarded, on average over \$4.65, has been returned to New Jersey for continued research, strengthening the scientific infrastructure and New Jersey's economy."



2 Year Awards

Rosalyn D. Blumenthal, Ph.D., Center for Molecular Medicine and Immunology / Garden State Cancer Center
áCEA-Directed Immunotherapy for Metastasis
\$96,200

Longqin Hu, Ph.D., Rutgers, The State University
Novel Bifunctional Dendrimers Targeting Tumor Cells
\$96,000

David M. Lukac, Ph.D., UMDNJ-New Jersey Medical School
Synergy of KSHV ORF57 with the Viral Lytic Switch Protein
\$48,901

Roderich E. Schwarz, M.D., Ph.D., UMDNJ-Robert Wood Johnson Medical School
The Cancer Institute of New Jersey
Ras Inhibition and Antiangiogenic VEGF-Directed Therapy of Pancreatic Cancer
\$97,900

1 Year Awards

Elise L. Lev, Ed.D., RN, Rutgers, The State University
Prospective Study of Quality of Life of Men Receiving Brachytherapy for Prostate Cancer
\$46,900

Hua Zhu, Ph.D., UMDNJ-New Jersey Medical School
A Novel Cytomegalovirus-Initiated Signal Pathway
\$49,500

Linda J. Patrick-Miller, Ph.D., UMDNJ - Robert Wood Johnson Medical School
The Cancer Institute of New Jersey
"The Impact of a Relative's Mammogram: A Teachable Moment"
\$34,249

Breast Cancer Research Fund Awards

Krishna V. Kesari, Ph.D., UMDNJ-Robert Wood Johnson Medical School
Role of HMGI-C Protein in Breast Cancer
\$100,000 (2 years)

Nagarajan Selvamurugan, Ph.D., UMDNJ-Robert Wood Johnson Medical School
TGF-beta Action on Human Breast Cancer Cells
\$97,900 (2 years)

David E. Axelrod, Ph.D., Rutgers, The State University
Quantitative Hispathology of Breast Carcinoma In Situ
\$97,802 (2 years)

Tsafi Pe'ery, Ph.D., UMDNJ-New Jersey Medical School
Granulin: Cyclin T1 Interactions in Breast Cancer
\$50,000 (1 year)

Eric N. Shiozaki, Princeton University
Structural Analysis of Caspase-9 Regulation
\$33,000 (predoctoral fellowship)

Breast Cancer RFA

To tap the expertise of people most affected by breast cancer, the Breast Cancer Advisory Group to the New Jersey Commission on Cancer Research has pioneered support for collaboration between research institutions.

Because the disease is still a major killer despite increased research efforts, new breakthroughs are likely to come from thinking outside established patterns of scientific thought. The NJCCR brings together scientists from different institutions to develop creative ideas outside traditional research channels.

Robert Wieder, M.D., Ph.D., UMDNJ-New Jersey Medical School
Jonathan Yavelow, Ph.D., The Sarnoff Corporation
Role of Bone Marrow Stromal FGF-2 in Breast Cancer Dormancy
\$150,000

New Jersey Cancer Research Fellowships

The New Jersey Cancer Research Fellowship program was initiated by the NJCCR in 1988 to attract and retain scholars pursuing careers in cancer research. Talented students continue to focus on a range of research projects that have contributed significantly to the scientific reputation of the State. In addition, jobs have been created, our technological base has been enhanced, and the quality of science has improved.

At a time when mentors are facing unstable funding sources and pressures to maintain programs when NIH resources are diminishing, the NJCCR finds it especially rewarding to be able to fund much needed fellowships that provide “hands on” laboratory experience to promising scholars.

These programs help establish the foundation for the level of scientific investigation that will keep New Jersey at the forefront in the war against cancer. Since its inception, this has proven to be a sound and promising investment, resulting over 350 papers published in peer-reviewed journals, in addition to numerous presentations at conferences internationally.

This year, the Commission was able to award three post-doctoral, eight pre-doctoral, and fifteen summer fellowships to students of outstanding merit.



Post Doctoral Fellowships

Kui Huang, Ph.D., Princeton University
Regulation of Cell Adhesion in Human Cancer
\$58,050

Jerome F. Kucharczak, Ph.D., UMDNJ-Robert Wood Johnson
Medical School
Antiapoptotic and Oncogenic Function of Ffl-1/A1
\$58,050

Jeonghyeon Park, Ph.D., Princeton University
Chromatin Modifying Complexes in Myc Oncogenesis
\$58,050

Pre Doctoral Fellowships \$33,000 each

Naomi Bergman, UMDNJ-New Jersey Medical School
Regulation of mRNA Turnover in Mammalian Cells

Amy E. Cocina, Princeton University
Structural Analysis of Two C. elegans Apoptotic Proteins

Yan C. Ji, Ph.D., UMDNJ-New Jersey Medical School
Signaling of Differentiation by 1,25D3 in Leukemia Cells

Ali Nouri, Princeton University
APC Tumor Suppressor's Role in Cell Migration

William Simmons, UMDNJ-New Jersey Medical School
Role of CD30 in the Growth Promotion of SJL Lymphomas

Scott J. Steele, Princeton University
Analyses of a Putative Imprinting Control Region

Nicholas S. Tolwinski, Princeton University
Wnt Signaling and the Control of Cell Morphology

Datsen Wei, Princeton University
Murine NKT Cell Development

Summer Research Fellowships \$2,800 each

Kelly Burke

The Cancer Institute of New Jersey

Priscilla Dzurich

Seton Hall University

Ishani Ganguli

Princeton University

David Kingery

Rutgers, The State University

Cheng Larry

Rutgers, The State University

Jason Luciano

Rutgers, The State University

Raakhee Mahajan

UMDNJ-New Jersey Medical School

Ronald Myers

Rutgers, The State University

Vanessa Nina

Garden State Cancer Center

Stephanie Nnadi

UMDNJ-Robert Wood Johnson Medical School

Nnenka Offor

Princeton University

Hammad Rizvi

Center for Advanced Biotechnology and Medicine

Michael Schmidt

Garden State Cancer Center

Jeong Deok Shaefer

Center for Advanced Biotechnology and Medicine

Jack Tsai

Rutgers, The State University

2002: A Year in Review

2002 Annual Retreat on Cancer Research

As in the past, the New Jersey Commission on Cancer Research and The Cancer Institute of New Jersey co-sponsored the *2002 Annual Retreat on Cancer Research in New Jersey*. This year's event was held at the Princeton Marriott on April 24, 2002, and was attended by over 500 researchers, allied health professionals, nurses, students, patients and advocates. The *Retreat* was expanded dramatically this year by incorporating five different sessions to accommodate interests from researchers, nursing & psychosocial professionals, prostate cancer researchers and the public.

The general session attracted over 350 cancer researchers, health care professionals and students from throughout New Jersey. This session featured as keynote speaker a world renown leader, Dr. Rudolph Jaenisch, Member of the Whitehead Institute and Professor of Biology at the Massachusetts Institute of Technology. Dr. Jaenisch discussed "The Cloning of Mammals: Problems and Promises".

Over 80 health professionals attended the nursing and psychosocial session and were treated to exciting talks by Drs. Susan Orel and Jon Kerner. Dr. Susan Orel, Associate Professor of Radiology at the University of Pennsylvania discussed new screening tools for breast cancer. Dr. Jon Kerner, Assistant Deputy Director for

Research Diffusion & Dissemination within the Division of Populations Sciences at the National Cancer Institute discussed "Closing the Discovery-Delivery Gap: A Model for Research-Practice Partnerships".

To keep New Jersey on the cutting edge of research, a new session was added with a focus on the emerging technologies in cancer research. Dr. James P. Basilion, Co-Director, National Foundation of Cancer Research, Center for Molecular Analysis and Imaging at Massachusetts General Hospital discussed "Non-Invasive Imaging of Gene Expression". Drs. Eric Eastman and William Baumbach of Morphochem, Inc. spoke about the "Integration of Chemistry, Biology, Genomics, and Informatics Aimed at Next-Generation Oncology Drugs". Dr. Sterling McBride, Senior Member, Technical Staff at Sarnoff Corporation ended the symposium discussing "Microfluidics: Applications in Biotechnology".

In connection with the Retreat, The Dean & Betty Gallo Prostate Cancer Center at The Cancer Institute of New Jersey sponsored a special prostate cancer symposium that showcased the innovative research being conducted within New Jersey and provided over 100 researchers and health professionals the opportunity to open channels of communication and develop closer collaborations. Keynote speakers included Gerald

R. Cunha, PhD, Professor of Anatomy and Urology, University of California, San Francisco; Philip Kantoff, MD, Director, The Lank Center for Genitourinary Oncology, Associate Professor of Medicine, Dana-Farber Cancer Institute; and Angelo DeMarzo, MD, PhD, Assistant Professor of Pathology, Urology and Oncology, Johns Hopkins University.


The public forum session of the Retreat focused on the early detection and causes of cancer. Presentations by Michael A. Gallo, Ph.D., Director, NIEHS Center of Excellence; Professor, UMDNJ-RWJMS, Elisa Bandera, M.D., Ph.D., Assistant Professor of Nutritional Sciences, Rutgers University, Siu Yao, M.D., Director of Clinical Oncology, Merck & Company, and Susan Orel, M.D., Associate Professor, Department of Radiology, University of Pennsylvania discussed exploring the link between the environment and cancer, the diet-cancer connection, and prostate cancer screening and mammography screening beliefs. Over 100 cancer patients and advocates attended and each departed with an increased awareness about controversial cancer issues and the availability of cancer innovations right here in New Jersey.

Poster presentations were held throughout the day featuring the excellent work being conducted in New Jersey. Each year, talented graduate and postdoctoral stu-

dents compete for the New Jersey Cancer Research Award for Scientific Excellence. Lilly, major sponsor of the program, along with several other major pharmaceutical companies, sponsored the following awards for outstanding presentations:

1. Lilly award to Elizabeth Alli, The Cancer Institute of New Jersey, for "Examination of Stathmin as a Potential Drug Target in Mutant P53 Cells"
2. Lilly award to Kurt Degenhardt, Center for Advanced Biotechnology and Medicine, for "Analysis of IL-10 and IL-10 Homologues in Human Cell Lines Derived from B Cell Malignancies"
3. Lilly award to Leonard Edelstein, Center for Advanced Biotechnology and Medicine, for "Mechanisms of Constitutive NJ-KB Activation in Human Prostate Cancer Cells"
4. Lilly award to Michael E. Lindy, UMDNJ-New Jersey Medical School, for "FGF-2 Promotes SHP-2-F-Actin Colocalization and Blocks Breast Cancer Cell Motility"
5. Lilly award to Dina Matheos, Princeton University, for "TRRAP-Dependent and TRRAP-Independent Transcriptional Activation by MYC Family Oncoproteins"

6. Lilly award to Elisabeth Memin, UMDNJ-New Jersey Medical School for “The PI3K/AKT Pathway Inhibits Sumoylation and Promotes Ubiquitination, Cytoplasm Translocation and Subsequent Degradation of ICER in PTEN-Negative Prostate Cancer and Glioblastoma Cells”
7. Amgen award to Gozde Ozakinci, Rutgers, The State University, for “Long-Term Impact of Genetic Testing for BRCA 1 and 2 Mutations on Self-Assessed Health, Optimism, Cancer Worries, and Quality of Life”
8. Amgen award to Carmela Palermo, UMDNJ-Robert Wood Johnson Medical School, for “Structure-Function Analysis of the C-Terminal Domain of CHK1”
9. Pfizer award to Trevor Reichman, UMDNJ-New Jersey Medical School, for “Enhanced Expression from the Proliferating Cell Nuclear Antigen Promoter by Interleukin Enhancer Binding Factor 3 Requires its Double-Stranded RNA Binding”
10. Pfizer award to Angelo Russo, The Cancer Institute of New Jersey, for “Altering the Balance of Thymidine Supply by Regulation of DHFR: A New Role for ARF”
11. Pharmacia Oncology award to Kathleen Sternas, Seton Hall University, for “Appraisal, Coping, and Lifestyle Patterns of Older and Younger Women with Breast Cancer”
12. Pharmacia Oncology award to Wei Zhang, Princeton University, for “Transcriptional Gene Expression Profiles of Colon Cancer: Gene Identification and Pattern Recognition”



Sharing Perspectives on Biomedical Research

The New Jersey Commission on Cancer Research and Rider University co-sponsored a conference for New Jersey's outstanding high school science students and teachers to allow them to experience a scientific meeting just like those that established researchers participate in. Over 150 students and teachers attended the event, which was held on the campus of Rider University on May 21, 2002.

Dr. Maureen Murphy, Associate Member, Medical Science Division at Fox Chase Cancer Center, began the day with an interactive dialogue with students about her background, career choice and research interests and provided information about colleges and universities that are prepared to mold students for careers in science or medicine.

Dr. Ned Lattime, Associate Director for Education and Training at the Cancer Institute of New Jersey and Professor of Surgery at UMDNJ-Robert Wood Johnson Medical School, explored the frontiers of cancer immunology and vaccine development and what's new in science education. His lecture focused on how to conduct research, an overview of the methods used in different

scientific disciplines and the latest technologies used in cancer research labs.

Students participated in poster presentations and round table career discussions with top New Jersey scientists. Shannon Callahan of Woodbridge High School and Juliet Girard of Dickinson High School were chosen to present their posters to their peers.

Teachers attended a professional development program sponsored by the Howard Hughes Medical Institute. Programs of this nature can help to develop curriculum and methods to prepare students for careers in science. By creating links between college programs and high school curriculum, it is possible to strengthen and enrich student's science background in New Jersey.

The symposium was well received by both high school teachers and students alike. Both benefited from learning about different perspectives and looked forward to applying their newfound knowledge in their respective schools. Tours of Rider Laboratories and the campus ended the day.

Working Together to Eradicate Cancer

Throughout its history, The New Jersey Commission on Cancer Research (NJCCR) has united with members of the cancer community so that we might work together to keep New Jersey on the cutting edge in the fight against cancer.

In 2002, Governor McGreevey's Task Force on Cancer Prevention & Control asked the NJCCR to review the New Jersey Comprehensive Cancer Plan as part of the planning process. NJCCR Members made a number of suggestions that were incorporated into the Plan. The Plan is expected to be released to the Governor in early 2003.

In addition, Commissioner Lacy approved \$525,000 from the De-

partment of Health and Senior Services' new cancer initiatives funding source to provide seed grants for pilot studies in 2002 that focus upon achieving the health promotion and disease prevention objectives in Healthy 2010 and the New Jersey Comprehensive Cancer Control Plan. The NJCCR will administer the funds through RFAs to be released in 2002 for up to 6 grant awards in 2003. RFA titles include: Cancer & Aging: A Call to Action; Investigating Disparity in Cancer Rates Among Ethnic Minorities and Medically Under-Served Populations; and Measuring and Assessing Quality of Life Outcomes in Cancer Care.

Demystifying Oncology Research: The Journey from Clinician to Educated Research Consumer and on to Investigator

The Nursing Psychosocial Advisory Group to the Commission revised and updated its highly successful *Demystifying Psychosocial Research* conference for nearly 50 health professionals from throughout New Jersey on June 5, 2002 at the American Cancer Society, New Brunswick offices. The purpose of the program was to help practitioners explore the need to properly understand and

evaluate research findings. In addition, the seminar was planned to encourage clinicians to consider participation in the research process and to appreciate the significant contribution that can be made to the knowledge that drives healthcare. Members of the Nursing/Psychosocial Advisory Group served as faculty and discussed the values of scientific evaluation, the role of clinical trials, evaluating the literature,

use of the web as a resource, current New Jersey research, finding and obtaining funding, and finally, translating the original thought into a definable research project. Participants came away from the program with the

basic skills needed to formulate critical research questions, develop study methodologies and locate possible funding sources. Additional seminars will be planned on a regional basis.

Demystifying Oncology Research Faculty

Denyse Adler, MA
President
The Adler Group

Ann Marie Hill, MBA
Executive Director
New Jersey Commission on
Cancer Research

Alan Axelrod, MSW
Coordinator, SeniorLink Program
The Princeton House

Mildred Ortu Kowalski, RN, MPA
Clinical Research Manager
Novartis Oncology

Wendy Budin, PhD, RN, BC
Associate Professor of Nursing
College of Nursing
Seton Hall University

Kathleen Neville, PhD, RN
Professor, Department of Nursing
Kean University

Robert Hallissey, PhD
Director of Grants and Research
Seton Hall University

Linda Patrick-Miller, PhD
Director, Division of Behavioral Sciences
The Cancer Institute of New Jersey

Cancer and Aging: A Call to Action

Exploring what is known and unknown about the unique aspects of cancer in the older adult was the challenge to a number of nationally recognized authorities presenting to the New Jersey healthcare community at the *Cancer and Aging, A Call to Action* conference held on October 4-5, 2002 at the Princeton Westin, Princeton, New Jersey. The conference, chaired by Drs. William A. Lerner, and David J. Sharon, was sponsored by the New Jersey Commission on Cancer Research (NJCCR), Meridian Health System and Saint Barnabas Health System, with administrative support from the UMDNJ-School of Public Health.

Thirteen outstanding experts (see faculty list) came to New Jersey to lead sessions on such diverse topics as “Screening Interventions in Older Adults”, “The Economics of Cancer and Our Aging Population”, “Pain and Palliative Care in Older Adults”, and “Practical Problems in Geriatric Oncology”. Presenters with varied backgrounds, many of whom are nationally renowned experts on the topic, helped to make this day a success. Experts from the National Institute on Aging, the American Pain Foundation, the NIH, Clinical Center, US Oncology, H. Lee Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center were among our guests.

Despite the accelerating numbers



of older adults with cancer, and the reality that more than one half of all new cancer diagnoses are found in this population, little special attention has been paid to meeting their unique and complex needs. Conference participants shared concerns about the lack of research focus and dissemination of information, frustrations relative to minimal or diminishing resources, and the urgency imposed by the scope of the rapidly growing population to be served.

As one might hope, representatives attended this two-day conference from many specialties including medical oncology, geriatrics, radiation oncology, social work, nursing, epidemiology and others. These specialists found much in this conference to enhance their understanding of the interface between senior status, co-morbidities, cancer and their specialties. The

audience welcomed the opportunity to review our current understanding of how the needs of the geriatric cancer population may be different from younger counterparts facing similar diagnoses and treatment, and how they often may be the same. The attendees seemed deeply committed to expanding their understanding of the senior cancer patients. However, it was also evident, as the speakers took the attendees through each topic, that we have learned little to date empirically regarding the screening and treatment impacting the more elderly cancer patient. It seems clear that the scientific community has failed to engage sufficient numbers of older cancer patients in clinical trials or consider them as a distinct population, thereby leaving us with less scientifically generated guidelines on which to base screening, treatment and rehabilitation decisions.

It was noted that the next challenge for healthcare is to correct these deficits so that clinical trials can answer questions that will positively impact on the care of elderly patients. We must strive to understand the myths and misinformation that raise barriers involving seniors in research, and even possibly, to health care providers offering seniors the opportunity to participate in trials.

The presenters sounded a hopeful note as they, almost to a person, congratulated New Jersey for taking a position on the topic of cancer and aging. They were enthusiastic

about this initiative, and were encouraged to see this topic as a focus for attention here in New Jersey, noting how few states have begun to address these issues.

The consensus of the conference has led to the development of a *New Jersey Cancer and Aging Task Force*, whose mission will be to promote a statewide, comprehensive and flexible vehicle that can identify priorities and design innovative implementation strategies to address the emerging and significant issues raised. The Task Force will include and collaborate with ongoing efforts in the State that are directed at the older adult, as well as other cancer-focused programs, to ensure a minimum of redundancy. Efforts to reduce the disparity of access to care among minority groups within the older adult community were identified as a high priority.

After consideration of several possible organizational structures including legislative, gubernatorial and the New Jersey Department of Health and Senior Services created entities, it was agreed that the New Jersey Commission on Cancer Research, as a state agency with broad experience supporting advisory boards/task forces and a demonstrated commitment to these issues, was the most suited to sponsor the task force under its administrative umbrella. This is especially appropriate as the conference findings indicated a significant need for research in this area.

It is hoped, that the energy and enthusiasm generated by the meeting will provide the impetus to change the way in which older adults are viewed, served and

cared for. The reality was clear: this is about all of us – each one of us and the patients we serve will, sooner or later, be in this population – and time is flying.

Cancer and Aging: A Call to Action Faculty

Joseph Bailes, MD

Executive Vice President
Clinical Affairs
US Oncology

Lodovico Balducci, MD

Director, Senior Adult Oncology
Professor, H. Lee Moffitt Cancer
Center

Ann Berger, MD

Chief, Pain & Palliative Service
NIH, Clinical Center

Deborah Boyle, RN, MSN

Practice Outcomes Nurse
Specialist
Good Samaritan Regional Medical
Center

Yvette Colón, MSW, ACSW

Director of Education and
Internet Services
American Pain Foundation

William B. Ershler, MD

Director, Institute for Advanced
Studies in Aging & Geriatric
Medicine

Martine Extermann, MD, PhD

Assistant Professor
H. Lee Moffitt Cancer Center

Jimmie Holland, MD

Chair, Dept of Psychiatry &
Behavioral Sciences
Memorial Sloan Kettering Cancer
Center

Laura Hutchins, MD

Director, Division of Hematology/
Oncology, Professor of Medicine
University of Arkansas for Medical
Sciences

William A. Lerner, MD

Chief, Division of Hematology-
Oncology; Medical Director, The
Cancer Center; Director, Hospice
Services; Medical Center of Ocean
County, Meridian Health System

Richard Payne, MD

Director, Pain & Palliative Services
Memorial Sloan Kettering Cancer
Center

David J. Sharon, MD

Chief, Division of Hematology-
Oncology; Medical Director, The
Cancer Center; Monmouth Medical
Center; Saint Barnabas Health Care
System

Rosemary Yancik, PhD

Chief, Cancer Section,
National Institute on Aging



**New Jersey
Breast Cancer
Research Fund**

The New Jersey Breast Cancer Research Fund

The New Jersey Breast Cancer Research Fund (BCRF), which is supported by contributions through the New Jersey state income tax return, had another successful year in FY 2001. The BCRF finished number one among income tax choices, raising over \$239,000 for breast cancer research.

When these funds are combined with private donations and other special project revenues, the NJCCR will be able to award more grants, fellowships, and scholarships to breast cancer researchers.

The Conquer Cancer License Plate

The NJCCR also administers the proceeds raised through the Conquer Cancer license plate. The plate is available at local Division of Motor Vehicle

offices and can be purchased at any time during the registration cycle for \$50 (\$42 goes to cancer research), with a \$10 annual renewal fee (100% of the renewal fee goes to cancer research projects).



In 2002, over 5,700 plates were sold, raising more than \$590,000, when renewal fees are included, for cancer research. With the consistent success of the license plate, New Jersey cancer researchers can look forward to additional grant and fellowship awards.

People + Passion = Power

That is the strength of cancer advocates in New Jersey. We are fortunate to have hundreds of talented volunteers who unselfishly contribute their time and expertise. Their skills, coupled with a passion to fight the war against cancer, provide an incredible power and energy to help people cope with cancer and fund research.

With each passing year, and each White Beeches charity affair, hope increases for people with cancer in New Jersey. The White Beeches Golf and Country Club, once again, had a banner year, raising over \$23,000 for cancer research.

On July 10, 2002, *The Ladies* at White Beeches Golf and Country Club in Haworth, N.J., sponsored a "Christmas in July" charity affair for patient aid and cancer research. The daylong event brought together over 250 women, who competed in bridge and golf tournaments. A wonderful luncheon and award ceremony followed, which also featured a Chinese auction.

On September 22, 2002, the Prostate Cancer Support Group at Morristown Memorial Hospital along with the Kidney & Urology Foundation of America sponsored a walk at the Lewis Morris County Park in Morristown, NJ. Over, 100 people walked in friendship, joy

and camaraderie with a common purpose: to increase awareness about prostate cancer and raise money for research.

One hundred percent of the proceeds from both events will support cancer research at non-profit institutions in New Jersey.

As more funding for cancer research is needed to support the many deserving and promising programs in New Jersey, the NJCCR is very grateful and fortunate to be the beneficiaries of these two very successful events.



New Jersey Commission on Cancer Research 2002 Revenue Summary



Commission Offices

New Jersey
Commission on
Cancer Research
28 West State Street
5th Floor
PO Box 360
Trenton, NJ 08625-0360

PHONE:

(609) 633-6552

FAX:

(609) 633-6814

EMAIL:

NJCCR@doh.state.nj.us

INTERNET WEB SITE:

[www.state.nj.us/health/
cancer.htm](http://www.state.nj.us/health/cancer.htm)

Revenues

State Appropriation (Cancer Research Fund)	\$1,000,000
Breast Cancer Research Fund	239,181
Conquer Cancer License Plate	619,915
Gifts, bequests, donations, grants	72,303

Total Revenues

\$1,931,399

Expenses

1. Awards

a.Grants	\$967,149
b.Fellowships	513,150
c.Scientific Meetings & Programs	156,100

2. Research management & support

295,000

Total Expenditures

\$1,931,399

Monies raised through the Breast Cancer Research Fund, the Conquer Cancer License Plate or from contributions do not finance the Commission's operat-

ing expenses. 100% of these contributions go directly to an approved cancer research project in New Jersey and are tax deductible.

2002 Commission Members and Staff

The overall objectives, strategies and priorities of the NJCCR are set by the Members, who actively participate in overseeing the program and make final recommendations on the research projects to be funded. In each Grant Cycle, the NJCCR awards grants based on the Member's recommendations, following peer reviewers' evaluations, assessment of responsiveness to program priorities, and available funds.

The NJCCR currently consists of nine members appointed by the Governor with the consent of the Senate: four scientists/clinicians; one member from a non-profit health organization, two members from private industry; one ex-officio member from the Department of Health and Senior Services, and one ex-officio member from the Department of Environmental Protection.



Commission Staff

Ann Marie Hill
Executive Director

Michael C. Toleno
Assistant Director

Shane Letezia
Grant Coordinator

Karen Schaefer
Secretarial Assistant



Paul E. Wallner, D.O., FACR Commission Chair

Dr. Wallner is Clinical Professor and Vice Chairman in the Department of Radiation Oncology at the University of Pennsylvania School of Medicine. He is Past-President of the Oncology Society of New Jersey and Past-President of the American Cancer Society, New Jersey Division, Inc. Dr. Wallner chairs the Core Clinical Advisory Group, and chaired the first State Cancer Plan Task Force for the New Jersey Department of Health and Senior Services. He served on the Board of Directors of the American Society for Therapeutic Radiology and Oncology and is a member of the Board of Chancellors of The American College of Radiology. Dr. Wallner resides in Moorestown, New Jersey.



Anna Marie Skalka, Ph.D. Commission Vice-Chair

Dr. Skalka has been the Senior Vice President for Basic Science and Director of the Institute for Cancer Research at the Fox Chase Cancer Center in Philadelphia since 1987. Previously, she chaired the Department of Molecular Oncology at the Roche Institute for Molecular Biology in Nutley. Dr. Skalka serves on a number of national and international scientific advisory committees, and on the editorial boards of several scientific journals. She was a recipient of an Outstanding Investigator Grant from the National Cancer Institute and an unrestricted grant for research in infectious diseases from the Bristol Myers Squibb Co. In 1994, in recognition of her outstanding achievements, Dr. Skalka was elected a Fellow of the American Academy of Arts and Sciences and in 1996 she was elected to the American Association for the Advancement of Science and the American Academy of Microbiology (AAM), serving on the Board of Governors from 1999-2002. Dr. Skalka is an internationally recognized expert on molecular genetics and the molecular biology of RNA tumor viruses. Dr. Skalka lives in Princeton, New Jersey.



Thomas Atherholt, Ph.D.

Dr. Atherholt is a member of the Division of Science, Research and Technology of the New Jersey Department of Environmental Protection (DEP) where he is a research microbiologist. Dr. Atherholt received his doctorate in microbiology from Rutgers University. He was a genetic toxicologist at the Coriell Institute for Medical Research in Camden, NJ, prior to joining the DEP in 1990. Dr. Atherholt serves as an ex-officio member representing the Commissioner of the Department of Environmental Protection. He was also awarded the Professional Achievement Award, by the State of New Jersey, for award-winning drinking water research, in May 2001. He resides in Moorestown, New Jersey.



Eddy A. Bresnitz, M.D., MS

Dr. Bresnitz is the New Jersey State Epidemiologist/Assistant Commissioner of Epidemiology, Environmental and Occupational Health Programs in the Department of Health and Senior Services. He oversees the Office of Cancer Control and Prevention and the Cancer Epidemiology Service in the Department. He is also Professor of Medicine in the Department of Environmental and Community Medicine in the Robert Wood Johnson Medical School and the School of Public Health of the University of Medicine and Dentistry of New Jersey. Dr. Bresnitz received his undergraduate and medical degrees from McGill University and a Master's of Clinical Epidemiology from the University of Pennsylvania. He completed postgraduate training at Montifiore Hospital in New York City and at the University of Pennsylvania and is board certified in internal, pulmonary and preventive medicine. He was formerly Chairman of the Department of Community and Preventive Medicine in the MCP Hahnemann School of Medicine in Philadelphia. Dr. Bresnitz has been principal investigator or co-principal investigator on a variety of NIH, foundation and state grants, and has published extensively, principally in the area of epidemiology and disease surveillance. Dr. Bresnitz serves as an ex-officio member representing the Commissioner of Health and Senior Services. Dr. Bresnitz resides in Lawrenceville, New Jersey.



Frederick B. Cohen, M.D.

Dr. Cohen served as Chairman of the New Jersey Commission on Cancer Research from 1987 – 2000. In addition, he was the Director of Medical Oncology from 1970 to 1999 and is past president of the medical staff of Newark Beth Israel Medical Center. He is recipient of the Edward J. Ill Award, one of the highest honors bestowed on a physician in New Jersey, and the New Jersey Pride Award in Health. He is past president of the Academy of Medicine of New Jersey and served as past president for the American Cancer Society, New Jersey Division, Inc. Dr. Cohen now serves as a principal investigator for the STAR project in addition to several clinical studies by national cooperative groups. He resides in South Orange, New Jersey.



George E. Dunaif, Ph.D.

Dr. Dunaif is the Senior Director - Toxicology and Analytical Services at the Campbell Soup Company, Camden. Dr. Dunaif directs the corporate and international toxicology and analytical laboratory programs and staff. In addition, he is the co-coordinator of the Campbell Integrated Pest Management Program. Dr. Dunaif received his Ph.D. in environmental toxicology from Cornell University. He is a diplomat of the American Board of Toxicology and has served on a number of national and international committees on nutrition and toxicology. He resides in Mount Laurel, New Jersey.



Lynn W. Enquist, Ph.D.

Dr. Enquist is a Professor of Molecular Biology at the Department of Molecular Biology at Princeton University. Previously, he was a Research Leader in Molecular Biology at Dupont and a Senior Research Fellow at DuPont-Merck Pharmaceutical Company. He was responsible for the DuPont-Merck Postdoctoral Fellowship Program and served as scientific advisor for senior management. In addition to teaching virology at Princeton, Dr. Enquist has published over one hundred seventy scientific papers and books. He has served on major scientific committees including the National Institutes of Health Experimental Virology Study Section and the Microbial Physiology and Genetics Study Section. Dr. Enquist is the Editor in Chief of the Journal of Virology, a fellow of the American Academy of Microbiology, and a fellow of the American Association for the Advancement of Science. He has lectured at numerous seminars and universities around the world. Dr. Enquist received his doctoral degree in Microbiology from the Medical College of Virginia. He resides in Princeton, New Jersey.



Barbara Rabinowitz, Ph.D.

Dr. Rabinowitz is the first Commission member to hold expertise in the psychological and psychosocial aspects of cancer. She completed her doctorate in Social Work at Rutgers University and is also a registered nurse. Dr. Rabinowitz completed three recent invited book chapters in textbooks for physicians on the psychosocial aspects of cancer care. She has published numerous articles, completed two important cancer research projects and presents papers to professional organizations nationwide. Dr. Rabinowitz is the Director of Oncology Services for Meridian Health System. In addition, she maintains a private practice in psychotherapy and sex therapy and resides in Lakewood, New Jersey.

Jeffrey A. Warren, M.P.A.

Jeffrey Warren is a Senior Advisor with the National Pharmaceutical Council. Previously he was responsible for Strategic Marketing and Media Relations for Pfizer Health Solutions. Prior to Pfizer, Jeff was Senior Director of Business Development for the Health Care Management unit of Parke-Davis, the pharmaceutical division of Warner/Lambert. Earlier in his career, Mr. Warren served as Executive Vice President, Corporate Development for Cathedral Healthcare System. During his tenure with Cathedral, Jeff was a National Program Director for the Robert Wood Johnson Foundation where he directed the New Jersey Health Services Development Program. Jeff's past experiences includes tenure as Vice President, Corporate Development with Hackensack Medical Center and serving as the first Administrative Director of the New Jersey Hospital Rate Setting Commission. Jeff is President of the Board of Gilda's Club of Northern NJ and a member of the board of Health Decisions. He also serves on the Editorial Task Force Committee of AMGA's "Group Practice Journal" and is a member of the Columbia University School of Public Health's Health Policy & Management Advisory Committee. Jeff has a Masters Degree (MPA) in Health Policy, Planning and Administration from the Wagner School of Public Service at NYU.

2002 Advisory Groups

The NJCCR has been fortunate in being able to work with a large number of health professionals, researchers, policy makers, and advocates from throughout New Jersey as part of

its Advisory Group structure. Many people have given generously of their time and expertise to contribute to the work of the Commission.

Advisory Group Highlights

The **Basic Research Advisory Group** to the NJCCR continues to develop innovative strategies for communicating the value of basic research with the public. A program implemented in 2002, "Sharing Perspectives in Biomedical Research", provided outstanding high school students to experience an actual scientific symposium, similar to those attended by active investigators.

The **Cancer Control and Prevention Advisory Group** embarked on a project that addresses the role of nutrition and cancer. This study will provide the baseline information needed to coordinate efforts in this area and develop more efficient statewide nutrition and cancer programs by identifying overlapping services and underserved populations.

The **Breast Cancer Research Advisory Group** is busy planning and implementing the 2003 Advances in Breast Cancer Research Symposium that will be held as part of the 2003 Annual Retreat on Cancer Research, June 11, 2003 at the Princeton Westin. Dr. Joe Gray, University of California, San

Francisco, Dr. Mina Bissell, Lawrence Berkley Laboratory, California, and Dr. Harry Bear, Medical College of Virginia are scheduled to speak. In addition, the Breast Cancer Advisory Group, along with New Jersey artists, created educational Breast Cancer Note Cards and is working towards publishing a 2004 Breast Cancer Research Calendar.

The **IMPACT NJ Advisory Group** seeks to reduce the barriers to enrollment in cancer clinical trials by addressing myths and building trust within communities. They will work with community leaders, research institutions, voluntary health care organizations and faith based groups to develop and implement a major educational initiative that will increase the amount of eligible patients to be enrolled in clinical trials. A particular focus will be in minority and medically underserved populations.

The **New Jersey Pediatric Hematology Oncology Network (NJPHON)** is focusing on cancer survivorship and long-term effects

of childhood cancers. Dr. Beverly Ryan chaired a roundtable on reproductive/sexuality problems in young adult survivors of childhood cancer in 2002. A report for primary care physicians was mailed to doctors throughout NJ explaining the findings from the event. Additional roundtables are planned for the future.

The **Joint Psychosocial & Nursing Advisory Group** hosted a very successful conference in 2002 called “*Demystifying Oncology Research: The Journey from Clinician to Educated Research Consumer and on to Investigator.*”

Basic Research Advisory Group

Chair:

Jonathan Yavelow, PhD

Rider University
Lawrenceville, NJ

Marie Hoover, PhD

Advanced Biomedical Laboratories
Cinnaminson, NJ

Elizabeth Raveche, PhD

UMDNJ-NJMS
Newark, NJ

Suzie Chen, PhD

Rutgers, The State University
Piscataway, NJ

Alice Y. -C Liu, PhD

Rutgers, The State University
Piscataway, NJ

Ian Whitehead, PhD

UMDNJ-NJMS
Newark, NJ

David Gold, PhD

Garden State Cancer Center
Belleville, NJ

Edith Postel, PhD

Princeton University
Princeton, NJ

Nancy Woychik, PhD

UMDNJ-RWJMS
Piscataway, NJ

Cancer Control and Prevention Advisory Group

Co-Chair:

Elisa Bandera, MD, PhD

The Cancer Institute of New Jersey
New Brunswick, NJ

Generosa Grana, MD

The Cooper Health System
Camden, NJ

Judith Klotz, DrPH

Advocate
Trenton, NJ

Co-Chair

Jane Lewis, DrPH

UMDNJ-School of Public Health
Piscataway, NJ

Marilyn Hansen, CTR

NJ Operations Cancer Program
Roselle Park, NJ

Cari Miller

The Peer Review Org of NJ
East Brunswick, NJ

Norma Almanza

The YA Group, Inc.
Union City, NJ

David Henry, MPH

Montgomery Twp Health Dept
Belle Mead, NJ

Mitch Rosen, MS

UMDNJ-School of Public Health
New Brunswick, NJ

Gilbert Baez, MSW

Overlook Hospital
Summit, NJ

Jun-Yan Hong, PhD

UMDNJ-RWJMS
Piscataway, NJ

Dona Schneider, PhD, MPH

Rutgers, The State University
New Brunswick, NJ

Gayle Cornish, RN, MPH

Morristown Memorial Hospital
Morristown, NJ

Shawna Hudson, PhD

The Cancer Institute of New Jersey
New Brunswick, NJ

Breast Cancer Research Advisory Group

Chair: Susan Rittling, PhD
Rutgers, The State University
Piscataway, NJ

The Honorable Rose Marie Heck
Assemblywomen, District 38
Lodi, NJ

Helen Richards
Patient Advocate
Haworth, NJ

Linda Basilio
Patient Advocate
Wallburg, NJ

Thomas J. Kearney, MD
The Cancer Institute of NJ
New Brunswick, NJ

Carmel Rutman
Patient Advocate
Paramus, NJ

Jeanne Beck, PhD
Coriell Institute of Medical Research
Camden, NJ

Judi Klein
Patient Advocate
Monmouth Junction, NJ

Mary Storms
Bristol-Myers Squibb Oncology
Kendell Park,, NJ

Kat Block
Patient Advocate
Springfield, NJ

Betsy Kohler, MPH
New Jersey Department of
Health & Senior Services
Trenton, NJ

Eva Sciandra
American Cancer Society
Stottville, NY 12172

Margaret Bryan, MD
UMDNJ-NJMS
Newark, NJ

Reju Korah, PhD
UMDNJ-NJMS
Newark, NJ

Dorothy Marie Wahlers
American Cancer Society
Toms River, NJ

Deborah M. Capko, MD
Hackensack Univ. Medical Center
Hackensack, NJ

Joyce Maso
Patient Advocate
New Brunswick, NJ

Barbara Waters
Susan G. Komen Breast
Cancer Foundation
Summit, NJ

Generosa Grana, MD
The Cooper Health System
Camden, NJ

Michael Reiss, MD
The Cancer Institute of NJ
New Brunswick, NJ

Robert Wieder, MD, PhD
UMDNJ-NJMS
Newark, NJ

Prostate Cancer Research Advisory Group

Chair: Robert DiPaola, MD
Cancer Institute of New Jersey
New Brunswick, NJ

Thea Greco
Patient Advocate
Roseland, NJ

George Rhoads, MD, MPH
Environmental and Occupational
Health Sciences Institute
UMDNJ-School of Public Health
Piscataway, NJ

H. Robert Carter
Patient Advocate
Little Silver, NJ

Stuart Leitner, MD
Saint Barnabas Health Care System
Livingston, NJ

Terry Roe
US Too!
Martinsville, NJ

Keith DaCosta
100 Black Men of New Jersey, Inc.
East Orange, NJ

Michael Perrotti, MD
UMDNJ-RWJMS
New Brunswick, NJ

Peter Doherty
Patient Advocate
Morristown, NJ

Don Reed
Patient Advocate
Hopewell, NJ

Cory Abate Shen, PhD
Center for Advanced
Biotechnology and Medicine
UMDNJ-RWJMS
Piscataway, NJ

IMPACT NJ Advisory Group **(Improving Minority & Medically Underserved** **Participation and Access to Clinical Trials)**

Chair:

Keith DaCosta

100 Black Men of New Jersey
East Orange, NJ

Roland Anglin, PhD

Center for Urban Policy Research
New Brunswick, NJ

Gilbert Baez, MSW

Overlook Hospital
Summit, NJ

Gerald Belgrave, DDS

Newark Community Health
Centers, Inc.
Newark, NJ

Gloria Boseman, PhD, RN

New Jersey City State Univ.
Jersey City, NJ

Jeannette Brummell

University Heights Science Park
Newark, NJ

Vicky Chen

American Cancer Society
Fords, NJ

Catherine Cuomo-Cecere

Newark Dpt. of Health & Human Ss.
Newark, NJ

Bonnie Evans

Kessler Rehabilitation Hospital
West Orange, NJ

Betty Gallo

Dean & Betty Gallo Prostate
Cancer Center at CINJ
New Brunswick, NJ

Beverly Henderson

100 Black Men of New Jersey
East Orange, NJ

Linda J. Holmes, MPA

NJ Dept. of Health & Senior Svs.
Trenton, NJ

Shawna Hudson, PhD

The Cancer Institute of New Jersey
New Brunswick, NJ

Laura Kudlacik, RN

Hackensack University Medical Ctr.
Hackensack, NJ

Jane Lewis, Dr.PH.

UMDNJ-School of Public Health
New Brunswick, NJ

Teresa M. Long, RN, BSN, MPA

Newark Dpt. of Health & Human Ss.
Newark, NJ

Julane Miller-Armbrister, MSW

Plainfield Neighborhood Health Ctr
Plainfield, NJ

Grace Nyatome, MD

St. Michaels Medical Center
Newark, NJ

The Honorable Douglas Palmer

Mayor, City of Trenton
Trenton, NJ

Karen L. Pennington, PhD

Montclair State University
Upper Montclair, NJ

Evelyn Robles-Rodriguez

Cooper Hospital/University Med Ctr
Camden, NJ

Denise V. Rodgers, MD

UMDNJ-RWJMS
New Brunswick, NJ

Arnold Rosenheck, DMD

UMDNJ-New Jersey Dental School
Newark, NJ

Dolores Tyson

Planned Parenthood of
Metropolitan New Jersey
Newark, NJ

New Jersey Pediatric Hematology Oncology Network

Chair: Peri Kamalakar, MD

Cynthia E. Gonzales, MD

Susan M. Murphy, MD

Ann G. Nepo, MD

Brenda C. Sison, MD

Saint Barnabas Medical Center
Livingston, NJ

Barry L. Barnoski, PhD

J. Phil McCoy, PhD

W. Roy Overton, PhD

Steven Paul, MD

The Cooper Health System
Camden, NJ

Wondwesson Bekele, MD

Peri Kamalakar, MD

Newark Beth Israel Medical Center
Newark, NJ

Barbara H. Greenbaum, MD

Susan F. Travis, MD

The Children's Hospital of
Philadelphia Specialty Center
Voorhees, NJ

Burton Appel, MD

Joel A. Brochstein, MD

Paola Conte, PhD

Steven Diamond, MD

Frances Flug, MD

Alfred Gillio, MD

John J. Gregory, MD

Steven Halpern, MD

Paul Harlow, MD

Michael B. Harris, MD

Larissa Labay, Psy.D.

Beverly R. Ryan, MD

Bruce N. Terrin, MD

Stephen Thompson, MD

Cindy S. Steele, MD

Cheryl Sterling, PhD

Gary A. Walco, PhD

Tomorrows Children's Institute
Hackensack, NJ

Justiniano F. Bagtas, MD

Wondwesson Bekele, MD

Peri Kamalakar, MD

Monmouth Medical Center
Long Branch, NJ

Michelle Miller, MD

James Powell, MD

Overlook Hospital
Summit, NJ

Richard Drachtman, MD

Renee Nigam, MD

Robert Wood Johnson
University Hospital
New Brunswick, NJ

Margarat Materson, MD

Peter Y. Ho, MD

Jersey Shore Medical Center
Neptune, NJ

Lawrence J. Ettinger, MD

Alice Ettinger, RN, CPNP

Cathy Lepnoitis, RN

Joan Rubin, CPON, CRA

St. Peter's University Hospital

Dona Schneider, PhD, MPH

Rutgers, The State University
New Brunswick, NJ

Joint Psychosocial/Nursing Advisory Group

Co-Chair:

Wendy Budin, PhD, RNC
Seton Hall University
South Orange, NJ

**Alice Ettinger, RN, MSN,
CPNP, CPON**
St. Peter's University Hospital
New Brunswick, NJ

Lois Lorenz, LCSW, Eds
American Cancer Society
Parsippany, NJ

Co-Chair:

Lissa Parsonnet, PhD
Private Practice
Short Hills, NJ

David Gordon, MS
Tomorrows Children's Institute
Hackensack, NJ

Judith Much, MSN, RN, CS, AOCN
The Cancer Institute of New Jersey
New Brunswick, NJ

Denyse Adler, MA
The Adler Group
Montville, NJ

Mildred Ortu Kowalski, RN, MPA
Novartis
East Hanover, NJ

Kathleen Neville, PhD, RN
Kean University
Union, NJ

Alan Axelrod, MSW
Princeton House
Princeton, NJ

Larissa Labay, Psy.D.
Tomorrows Children's Institute
Hackensack, NJ

Linda J. Patrick-Miller, PhD
The Cancer Institute of New Jersey
New Brunswick, NJ

Donna Bocco
DCB Associates
Freehold, NJ

Ellen Levine, LCSW
Cancer Institute of New Jersey
New Brunswick, NJ

Kathleen Walsh Scura, EdD, RN
William Paterson University
Wayne, NJ

John R. deVelder
Robert Wood Johnson
Univ. Hospital
New Brunswick, NJ

Ruth Lin, RN, MS, AOCN
Morristown Memorial Hospital
Morristown, NJ

New Jersey
Commission
on Cancer
Research

Annual
Report
2002



James E. McGreevey
Governor